Publications

If you would like to receive a full-text copy of any of the content listed below, email ma@admabio.com.

To expedite your request, please include the title of the content, your first and last name, healthcare designation (MD, NP, etc.) and business address.

Designation

Clinical & Real-World Data

Case Report: ASCENIV Use in Three Young Children with Immune Abnormalities and Acute Respiratory Failure Secondary to RSV Infection

Authors:Bindernagel C, Sotoudeh S, Nguyen M, Wetzstein G, Sriaroon P, Walter J

Published: Front Immunol. 2023;14:1154448

Response to Asceniv Treatment in a Case Series of Patients with Antibody Deficiency and Related Infections Refractory to Conventional Immunoglobulin Replacement Therapy

Authors:Tambay A, Loop L, Siri D, Geng B

Poster presented at: Aspen 2023 Annual Allergy Conference; July 30 - August 3, 2023; Aspen, CO.

In-vivo and Human Evidence for Potential Efficacy of Therapeutic Polyclonal RSV Neutralizing Antibodies for Palivizumab-resistant RSV Infections

Authors:Ramirez KA, Mond J, Papenburg J, Boivin G, Gilbert BE, Falsey AR, Bagga B, DeVincenzo JP

Published: Virology. 2023; 586:115-121

Case Report of Real-World Use of human-slra 10% through Subcutaneous Infusion

Authors:Loop L, Geng B

Poster presented at: The European Academy of Allergy and Clinical Immunology (EAACI) Congress; June 9-11, 2023; Hamburg, Germany

Treatment Response to Unique Blend IVIG with High Titers to RSV and Common Respiratory Pathogens in Patients with Antibody Deficiency and Chronic Lung Disease

Authors:Loop L, Tambay A, Geng B

Poster presented at: The European Academy of Allergy and Clinical Immunology (EAACI) Congress; June 9-11, 2023; Hamburg, Germany

Reductions in Infections and Associated Complications in Nine Common Variable Immunodeficiency Patients Treated with Immune globulin intravenous, human-slra

Authors:Huss J, McNeil D, Melton S, Myers G

Published: Poster presented at: The Eastern Allergy Conference Annual Meeting; June 1-4, 2023; Palm Beach, FL

Case Study: Successful Transition to ASCENIV Therapy with Improved PROMs

Authors:Prosser B, Miller C

Poster presented at: CIS 2023 Annual Meeting; May 18-21, 2023; St Louis, MO

Case Study: Successful Transition to ASCENIV Therapy with Improved PROMs

Authors:Prosser B, Miller C, Walton T

Published: Clin Immunol. 2023;250(Supp):109445

ASCENIV™ utilization in a primary immunodeficiency patient with recurrent viral infections

Authors:Rosenbach KP, Greener BN, Rosenbach JT, Wetzstein GA

Published: Immunol Med. 2023;46(1):58-60

Treatment with intravenous immune globulin 10% in a real-world outpatient setting

Authors:Herrscher R, Rosenbach K, Luu Q, Kim-Romo D, Van Anglen L

Poster presented at: AAAAI 2023 Annual Meeting; February 24-27, 2023; San Antonio, TX

Real-world utilization of immune globulin intravenous 10% at physician office infusion centers

Authors:Herrscher R , Luu Q, Kim-Romo D, Van Anglen L

Poster presented at: ACAAI 2022 Annual Scientific Meeting; November 10-14, 2022; Louisville, KY

Real-world evaluation of immune globulin intravenous 10% in the treatment of primary immunodeficiency

Authors:Van Anglen L, Kim-Romo D

Poster presented at: IgNS 2022 11th National Conference; September 29-October 2, 2022; Washington, DC

Review of ASCENIV in Two Young Males with Immune Abnormalities and RSV-Induced Respiratory Failure: A Case Series

Authors:Bindernagel C, Sullivan S, Miranda MA, Timothy P, Wetzstein G, Sriaroon P, Walter J

Poster presented at: The Florida Allergy, Asthma & Immunology Society (FAAIS) 2022 Annual Meeting; July 15-17, 2022; Orlando, FL

ASCENIV™ reduces viral infections and associated comorbidities in a primary immunodeficiency patient

Authors:Rosenbach K, Greener B, Rosenbach J, Wetzstein G

Poster presented at: CIS 2022 Annual Meeting; March 31-April 3, 2022; Charlotte, NC

Use of ASCENIV™ in a young male with immune abnormalities and multiviral-induced respiratory failure

Authors:Bindernagel C, Sullivan S, Miranda MA, Timothy P, Wetzstein G, Sriaroon P, Walter, J

Poster presented at: AAAAI 2022 Annual Meeting; February 25-28, 2022; Phoenix, AZ

Clinical impact of concomitant use of a novel high-titer immune globulin in an adult with COVID-19 and severe acute respiratory distress syndrome (ARDS)

Authors:Wetzstein GA, Ismail M, Gruenglas J, Decker D, Mond J

Poster presented at: 2021 International Society for Influenza and Other Respiratory Virus Diseases—World Health Organization (ISIRV-WHO) Virtual Conference; October 19-21, 2021

Kinetics of post-vaccination seroprotection to S. pneumoniae for the immune-compromised and vaccine-naïve populations

Authors:Mond J, Scobie M, Tolman C, Gruenglas J, Martinez J

Poster presented at: IDWeek 2021 Virtual Conference; September 29-October 3, 2021

RI-002, an intravenous immunoglobulin containing high titer neutralizing antibody to RSV and other respiratory viruses for use in primary immunodeficiency disease and other immune compromised populations

Authors:Wasserman RL, Greener BN, Mond J

Published: Expert Rev Clin Immunol. 2017;13(12):1107-1119

Efficacy, safety, and pharmacokinetics of a new 10% liquid intravenous immunoglobulin containing high titer neutralizing antibody to RSV and other respiratory viruses in subjects with primary immunodeficiency disease

Authors:Wasserman RL, Lumry W, Harris J III, Levy R, Stein M, Forbes L, Cunningham-Rundles C, Melamed I, Kobayashi A, Du W, Kobayashi R

Phase 3 study published: J Clin Immunol. 2016;36(6):590-599

Analysis of specific antibody levels in PIDD patients enrolled in a pivotal trial with an IVIG containing high titer neutralizing antibody to RSV

Authors:Mond J, Orange J, Du W, Kobayashi A, Kobayashi R, Cunningham-Rundles C, Lumry W, Harris J III, Levy R, Stein M, Forbes L, Melamed I, Kestenberg K, Wasserman RL

Poster presented at: CIS 2015 Annual Meeting Immune Deficiency & Dysregulation North American Conference; April 9-12, 2015; Houston, TX

Preclinical Data

Treatment with novel RSV Ig RI-002 controls viral replication and reduces pulmonary damage in immunocompromised Sigmodon hispidus

Authors:Boukhvalova M, Blanco JCG, Falsey AR, Mond J

Published: Bone Marrow Transplant. 2016;51(1):119-126

Therapeutic immunoglobulin selected for high antibody titer to RSV also contains high antibody titers to other respiratory viruses

Authors:Orange JS, Du W, Falsey AR

Published: Front Immunol. 2015;6:431

Compassionate Use

Treatment of RSV lower respiratory tract infection in two immunocompromised children with polyclonal immunoglobulin containing standardized levels of neutralizing anti-RSV antibodies

Authors:Levy ER, Madigan T, Binnicker MJ, Mond J, Huskins WC

Poster presented at: IDWeek; October 5, 2019; Washington, DC

Compassionate use experience with high-titer respiratory syncytical virus (RSV) immunoglobulin in RSV-infected immunocompromised persons

Authors:Falsey AR, Koval C, DeVincenzo JP, Walsh EE

Published: Transpl Infect Dis. 2017;19(2):10.1111/tid.12657

IVIG Manufacturing Overview

Manufacturing process optimization of ADMA Biologics’ intravenous immunoglobulin products, BIVIGAM® and ASCENIV™

Authors:Wasserman RL, Garcia D, Greener BN, Kestenberg K, Pinkert A, Mond J, Grossman A

Published: Immunotherapy. 2019 Nov;11(16):1423-1433

Health Policy

Ethical assessment of post-exposure prophylaxis

Authors:Gruenglas J, Mond J

Published: The Journal of Healthcare Ethics and Administration. 2021 Aug 12; 29:37

Health Economics and Outcomes Research

Pharmacoeconomic analysis of a unique immune globulin containing a blend of high-titer RSV and normal source plasma compared with IVIG+palivizumab in a patient with SCID

Authors:Gruenglas J, Miller R, Wetzstein G, Carneiro R

Poster presented at: Fifth International Conference on PharmScience Research & Development; February 21-24, 2023; Las Vegas, NV

Patient support facilitates access to IVIG therapy: interim results of a hub health program

Authors:Gruenglas J, Carneiro R, Karalian A

Poster presented at: IgNS 2022 11th National Conference; September 29-October 2, 2022; Washington, DC

Pharmacoeconomic analysis comparing medical costs for prophylaxis of HIV and HBV infection in sexual assault patients

Authors:

Gruenglas J, Pantello D, Mond J

Published:

Virtual AMCP 2021 Conference; April 12-16, 2021

Medical Survey Research

Respiratory viral infections continue to be an unresolved problem in the care of immunocompromised transplant patients

Authors:Wetzstein G, Decker D, Mond J

Poster presented at: National Comprehensive Cancer Network 2021 Virtual Annual Conference; March 18-20, 2021

Respiratory viral infections continue to be a growing problem in the care of hematopoietic cell transplanted patients

Authors:Wetzstein G, Decker D, Mond J

Poster presented at: The 2021 Transplantation and Cellular Therapy Meetings Digital Experience; February 8-12, 2021

Respiratory syncytial virus infections continue to be a growing problem in the care of immunocompromised patients receiving transplants

Authors:Wetzstein G, Decker D, Mond J

Poster presented at: International Society for Influenza and Other Respiratory Virus Diseases "RSV Webinar Series"; February 2021

If you would like to receive a full-text copy of any of the content listed below, email ma@admabio.com.

To expedite your request, please include the title of the content, your first and last name, healthcare designation (MD, NP, etc.) and business address.

Clinical & Real-World Data

Preclinical Data

Compassionate Use

IVIG Manufacturing Overview

Health Policy

Health Economics and Outcomes Research

Medical Survey Research

You are now leaving admabiologics.com

The link you have selected will take you outside of the ADMA Biologics corporate website. The site you will be entering is intended for US audiences only. Do you wish to continue?

Are you a healthcare professional?

This information is aimed exclusively at authorized US healthcare providers to prescribe or supply medicinal products and its correct interpretation requires specialized training.